![]() ![]() ![]() NantCell is a private subsidiary of NantWorks, LLC, is a clinical stage immuno-oncology company focused on developing novel molecularly targeted therapeutics including antibody, T-cell and NK cell based treatments for patients with cancer. On July 28, 2017, CytRX announced that it has entered a strategic license agreement with NantCell, Inc., for the exclusive rights to develop and commercialize aldoxorubicin for all indications.Preclinical data in animal models of pancreatic, ovarian, and non-small cell lung cancers show superior anti-tumor effects compared to gemcitabine while using approximately one-sixth of the dose. CytRx released its initial findings at the 2016 annual meeting of the American Association of Cancer Research. This drug is a derivative of the chemotherapeutic agent gemcitabine combined with a dual releasing linker. The company is also in the early stages of development of a compound known as DK049. At this time, the company expects to initiate a rolling new drug application for aldoxorubicin as a treatment for STS in the fourth quarter of 2017, with commercialization projected for 2018. Aldoxorubicin was subsequently granted orphan drug designation and no further clinical trials were requested. It also achieved a statistically significant improvement in the disease control rate.ĬytRx met with the FDA in March 2017 to discuss a regulatory approval pathway. Aldoxorubicin demonstrated a significant improvement in progression-free survival over the investigator’s choice therapy in 246 patients with either leiomyosarcoma or liposarcoma. The company released updated Phase III data in November 2016. The potential applications of aldoxorubicin are summarized in the CytRx’s pipeline: Other potential advantages of aldoxorubicin include the potential to increase the total doxorubicin dose, a reduction in certain adverse events associated with doxorubicin, and improved efficacy. ![]() Aldoxorubicin binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of the tumor. The company’s primary product candidate is designed to improve on doxorubicin, a widely-used chemotherapy agent. The company is also engaged in the development of a new class of oncology candidates utilizing their proprietary LADR technology.ĬytRx was originally incorporated in 1985, and is headquartered in Los Angeles, California. CytRx’s lead product candidate is aldoxorubicin, an alternative to widely-used chemotherapy agent doxorubicin.Īldoxorubicin is currently in late-stage development for the treatment of relapsed soft tissue sarcoma (STS), and is also being evaluated for several other cancer indications including small-cell lung cancer. In particular, the company is focused on anti-cancer drugs that employ linker technologies to enhance the accumulation and release of drugs at the tumor site. CytRx Corporation (NASDAQ: CYTR) is a clinical-stage pharmaceutical company specializing in oncology. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |